Gene expression profiles in premenopausal women with HR+ HER2 − early breast cancer

Background: Early breast cancer (EBC) is not a single disease but consists of several clinically relevant molecular subtypes. Within hormone receptor positive (HR+), HER2 negative (HER2 −) disease, different luminal subtypes (A vs. B) impact on outcome and response to endocrine therapy. Gene expression signatures predicting risk of recurrence are already part of clinical management. Gene profiles correlated with important tumor pathways such as metastasis and progression, immune response or proliferation also correlate with clinical outcome and therapy response.

Source: European Journal of Cancer - September 30, 2020 Category: Cancer & Oncology Authors: H. Ni, A. Kurt, J. Kumbrink, A. Seiler, D. Mayr, T. Degenhardt, F. Hagemann, R. W ürstlein, N. Harbeck, T. Eggersmann Tags: POSTERS A: Basic Science and Translational Research Source Type: research